Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?

Published on 2 Mar 2023 on Zacks via Yahoo Finance

Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Sorrento Therapeutics SRNEQ may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 15 cents per share for SRNEQ, compared to a broader Zacks Consensus Estimate of a loss of 19 cents per share. This suggests that analysts have very recently bumped up their estimates for SRNEQ, giving the stock a Zacks Earnings ESP of +21.05% heading into earnings season.

Sorrento Therapeutics, Inc. Price and EPS Surprise

Read the rest of the article

NASDAQ.SRNE price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?

NASDAQ.SRNE price evolution

Want to become a better investor?

Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?

Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing

An Update On Sorrento: Hitting Rock Bottom And Finding A Shovel (NASDAQ:SCLX)

Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's...

Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork

Sorrento Therapeutics Files for Bankruptcy to Halt $173 Million Licensing Judgments

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.11%

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.11%

ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances (NASDAQ:IBRX)

Sorrento Touts Positive Early-Stage Trial Data From Oral COVID-19 Therapy